PGRMC1 in animal breast cancer tissue and blood is associated with increased tumor growth with norethisterone in contrast to progesterone and dydrogesterone: four-arm randomized placebo-controlled xenograft study

References

• Mueck AO, Ruan X. Benefits and risks during HRT: main safety issue breast cancer. Horm Mol Biol Clin Investig. 2011;5(2):105–116.
   PubMedGoogle Scholar
• Gompel A, Plu-Bureau G. Progesterone, progestins and the breast in menopause treatment. Climacteric. 2018;21(4):326–332.
   PubMed Web of Science ®Google Scholar
• WHI Investigators (Chlebowski RT, et al.). Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. 2002;288:321–333.
   PubMed Web of Science ®Google Scholar
• Seeger H, Mueck AO. Are the progestins responsible for breast cancer risk during hormone therapy in the postmenopause? Experimental vs. clinical data. J Steroid Biochem Mol Biol. 2008;109(1–2):11–15.
   PubMed Web of Science ®Google Scholar
• Stahlberg C, Pedersen AT, Lynge E, et al. Hormone replacement therapy and risk of breast cancer: the role of progestins. Acta Obstet Gynecol Scand. 2003;82(7):335–344.
   Web of Science ®Google Scholar
• Gadducci A, Biglia N, Cosio S, et al. Progestagen component in combined hormone replacement therapy in postmenopausal women and breast cancer risk: a debated clinical issue. Gynecol Endocrinol. 2009;25(12):807–815.
   PubMed Web of Science ®Google Scholar
• Cordina-Duverger E, Truong T, Anger A, et al. Risk of breast cancer by type of menopausal hormone therapy: a case–control study among post-menopausal women in France. PLOS One. 2013;8(11):e78016.
   PubMed Web of Science ®Google Scholar
• Trabert B, Sherman ME, Kannan N, et al. Progesterone and breast cancer. Endocr Rev. 2019;41:1–25.
   Web of Science ®Google Scholar
• Pasqualini JR. Progestins and breast cancer. Gynecol Endocrinol. 2007;23(sup1):32–41.
   PubMed Web of Science ®Google Scholar
• Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2007;107(1):103–111.
   PubMed Web of Science ®Google Scholar
• Ruan X, Mueck AO. The choice of progestogen for HRT in menopausal women: breast cancer risk is a major issue. Horm Mol Biol Clin Investig. 2018;37:1–8.
   Web of Science ®Google Scholar
• Stanczyk FZ. Can the increase in breast cancer observed in the estrogen plus progestin arm of the Women’s Health Initiative trial be explained by progesterone receptor membrane component 1? Menopause. 2011;18(8):833–834.
   PubMed Web of Science ®Google Scholar
• Ruan X, Zhang Y, Mueck AO, et al. Increased expression of progesterone receptor membrane component 1 is associated with aggressive phenotype and poor prognosis in ER-positive and negative breast cancer. Menopause. 2017;24(2):203–209.
   PubMed Web of Science ®Google Scholar
• Neubauer H, Yang Y, Seeger H, et al. The presence of a membrane-bound progesterone receptor sensitizes the estradiol-induced effect on the proliferation of human breast cancer cells. Menopause. 2011;18(8):845–850.
   PubMed Web of Science ®Google Scholar
• Ruan X, Schneck H, Schultz S, et al. Nomegestrol acetate sequentially or continuously combined to estradiol did not negatively affect membrane-receptor associated progestogenic effects in human breast cancer cells. Gynecol Endocrinol. 2012;28(11):863–866.
   PubMed Web of Science ®Google Scholar
• Zhou J, Yu Q, Chen R, et al. Medroxyprogesterone acetate-driven increase in breast cancer risk might be mediated via cross-talk with growth factors in the presence of progesterone receptor membrane component-1. Maturitas. 2013;76(2):129–133.
   PubMed Web of Science ®Google Scholar
• Schneck H, Ruan X, Seeger H, et al. Membrane-receptor initiated proliferative effects of dienogest in human breast cancer cells. Gynecol Endocrinol. 2013;29(2):160–163.
   PubMed Web of Science ®Google Scholar
• Neubauer H, Ruan X, Schneck H, et al. Overexpression of progesterone receptor membrane component 1: possible mechanism for increased breast cancer risk with norethisterone in hormone therapy. Menopause. 2013;20(5):504–510.
   PubMed Web of Science ®Google Scholar
• Neubauer H, Ma Q, Zhou J, et al. Possible role of PGRMC1 in breast cancer development. Climacteric. 2013;16(5):509–513.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Ruan X, Wang H, et al. The presence of a membrane-bound progesterone receptor induces growth of breast cancer with norethisterone but not with progesterone: a xenograft model. Maturitas. 2017;102:26–33.
   PubMed Web of Science ®Google Scholar
• Ruan X, Gu M, Cai G, et al. Progestogens and PGRMC1-dependent breast cancer tumor growth: an in-vitro and xenograft study. Maturitas. 2019;123:1–8.
   PubMed Web of Science ®Google Scholar
• Zhang D, Xia X, Wang X, et al. PGRMC1 is a novel potential tumor biomarker of human renal cell carcinoma based on quantitative proteomic and integrative biological assessments. PLoS One. 2017;12(1):e0170453.
   PubMed Web of Science ®Google Scholar
• Ruan X, Cai G, Mueck A. Can blood concentrations of progesterone receptor membrane component-1 (PGRMC1) predict the risk of patients with breast cancer? Maturitas. 2019;124:183.
   Google Scholar
• Clark NC, Friel AM, Pru CA, et al. Progesterone receptor membrane component 1 promotes survival of human breast cancer cells and the growth of xenograft tumors. Cancer Biol Ther. 2016;17(3):262–271.
   PubMed Web of Science ®Google Scholar
• Mir SU, Ahmed IS, Arnold S, et al. Elevated progesterone receptor membrane component 1/sigma-2 receptor levels in lung tumors and plasma from lung cancer patients. Int J Cancer. 2012;131(2):E1–E9.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Ruan X, Willibald M, et al. May progesterone receptor membrane component 1 (PGRMC1) predict the risk of breast cancer? Gynecol Endocrinol. 2016;32(1):58–60.
   PubMed Web of Science ®Google Scholar
• Mueck AO, Ruan X, Seeger H, et al. Genomic and non-genomic actions of progestogens in the breast. J Steroid Biochem Mol Biol. 2014;142:62–67.
   PubMed Web of Science ®Google Scholar
• Willibald M, Bayer G, Stahlhut V, et al. Progesterone receptor membrane component 1 is phosphorylated upon progestin treatment in breast cancer cells. Oncotarget. 2017;8(42):72480–72493.
   PubMedGoogle Scholar
• Gu M, Wang L, Yang C, et al. Micro-RNA-181a suppresses progestin-promoted breast cancer cell growth. Maturitas. 2018;114:60–66.
   PubMed Web of Science ®Google Scholar